ea0011p616 | Neuroendocrinology and behaviour | ECE2006
Miller CL
, Palalau A
, Toogood AA
, Gittoes NJL
The most effective means of treating macroprolactinomas, including those associated with significant visual loss at presentation, is with dopamine agonist (DA) therapy. Improvement in visual function often occurs within days of commencing DA therapy, and usually precedes significant reductions in prolactin (PRL) concentrations and may predate significant evidence of tumour volume reduction by months or years. The temporal association between PRL concentration reductions and tu...